Compare Cipla with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON CIPLA/
BIOCON
 
P/E (TTM) x 29.3 32.9 89.1% View Chart
P/BV x 4.1 3.9 105.7% View Chart
Dividend Yield % 0.5 0.3 196.7%  

Financials

 CIPLA   BIOCON
EQUITY SHARE DATA
    CIPLA
Mar-20
BIOCON
Mar-19
CIPLA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs586707 82.8%   
Low Rs357554 64.4%   
Sales per share (Unadj.) Rs207.091.9 225.3%  
Earnings per share (Unadj.) Rs18.616.7 111.3%  
Cash flow per share (Unadj.) Rs33.224.2 137.2%  
Dividends per share (Unadj.) Rs4.001.00 400.0%  
Dividend yield (eoy) %0.80.2 535.3%  
Book value per share (Unadj.) Rs195.5101.6 192.3%  
Shares outstanding (eoy) m806.35600.00 134.4%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.36.9 33.2%   
Avg P/E ratio x25.337.7 67.1%  
P/CF ratio (eoy) x14.226.1 54.5%  
Price / Book Value ratio x2.46.2 38.8%  
Dividend payout %21.56.0 359.4%   
Avg Mkt Cap Rs m379,912378,330 100.4%   
No. of employees `00025.86.1 421.5%   
Total wages/salary Rs m30,27011,653 259.8%   
Avg. sales/employee Rs Th6,459.68,994.3 71.8%   
Avg. wages/employee Rs Th1,171.21,900.7 61.6%   
Avg. net profit/employee Rs Th580.21,635.3 35.5%   
INCOME DATA
Net Sales Rs m166,94955,144 302.8%  
Other income Rs m3,4421,444 238.4%   
Total revenues Rs m170,39156,588 301.1%   
Gross profit Rs m32,06015,883 201.9%  
Depreciation Rs m11,7474,478 262.3%   
Interest Rs m1,974709 278.4%   
Profit before tax Rs m21,78212,140 179.4%   
Minority Interest Rs m-4759 -5,273.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3122,123 297.3%   
Profit after tax Rs m14,99510,026 149.6%  
Gross profit margin %19.228.8 66.7%  
Effective tax rate %29.017.5 165.7%   
Net profit margin %9.018.2 49.4%  
BALANCE SHEET DATA
Current assets Rs m117,03848,228 242.7%   
Current liabilities Rs m43,93130,376 144.6%   
Net working cap to sales %43.832.4 135.3%  
Current ratio x2.71.6 167.8%  
Inventory Days Days9668 140.2%  
Debtors Days Days8586 99.5%  
Net fixed assets Rs m107,42464,130 167.5%   
Share capital Rs m1,6133,000 53.8%   
"Free" reserves Rs m156,01857,980 269.1%   
Net worth Rs m157,63060,980 258.5%   
Long term debt Rs m23,69315,766 150.3%   
Total assets Rs m236,626121,924 194.1%  
Interest coverage x12.018.1 66.4%   
Debt to equity ratio x0.20.3 58.1%  
Sales to assets ratio x0.70.5 156.0%   
Return on assets %7.28.8 81.4%  
Return on equity %9.516.4 57.9%  
Return on capital %12.816.8 76.6%  
Exports to sales %33.028.1 117.5%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs m55,17515,506 355.8%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m56,03615,506 361.4%   
Fx outflow Rs m6,76410,399 65.0%   
Net fx Rs m49,2725,107 964.8%   
CASH FLOW
From Operations Rs m30,68511,546 265.8%  
From Investments Rs m1,040-7,138 -14.6%  
From Financial Activity Rs m-29,488-2,417 1,220.0%  
Net Cashflow Rs m2,3402,103 111.3%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 25, 2021 (Close)

TRACK CIPLA

CIPLA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE CIPLA WITH

MARKET STATS